Document is current
Any future updates will be listed below
-
Authors
,
Jackson, Michael L. https://orcid.org/0000-0002-2340-0256
Hart, Gregory R.
McCulloch, Denise J.
Adler, Amanda
Brandstetter, Elisabeth
Fay, Kairsten
Han, Peter
Lacombe, Kirsten
Lee, Jover
Sibley, Thomas R.
Nickerson, Deborah A.
Rieder, Mark J.
Starita, Lea
Englund, Janet A.
Bedford, Trevor
Chu, Helen
Famulare, Michael
-
Funding
Funding for this research was provided by:
Gates Ventures
- License Information
-
More Information
Article History
Received: 17 September 2020
Accepted: 31 March 2021
First Online: 9 April 2021
Declarations
:
: The study was approved by the institutional review board at the University of Washington (protocol #00006181). Informed consent for residual sample and clinical data collection was waived, as these samples were already collected as part of routine clinical care, and it was not possible to re-contact these individuals.
: Not applicable.
: Michael L. Jackson has received grant funding from Sanofi Pasteur, unrelated to the present work. Janet A. Englund is a consultant for Sanofi Pasteur and Meissa Vaccines, Inc., and receives research support from GlaxoSmithKline, AstraZeneca, and Novavax. Helen Chu is a consultant for Merck and GlaxoSmithKline. Gregory R. Hart, Denise J. McCulloch, Amanda Adler, Elisabeth Brandstetter, Kairsten Fay, Peter Han, Kirsten Lacombe, Jover Lee, Thomas R. Sibley, Deborah A. Nickerson, Mark J. Rieder, Lea M. Starita, Amanda Adler, Trevor Bedford, and Michael Famulare declare no competing interests.
